{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["almonertinib", "docking", "icotinib", "olmutinib", "similarity search"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34770832", "DateCompleted": {"Year": "2021", "Month": "12", "Day": "03"}, "DateRevised": {"Year": "2021", "Month": "12", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "10", "Day": "24"}], "Language": ["eng"], "ELocationID": ["6423", "10.3390/molecules26216423"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "26", "Issue": "21", "PubDate": {"Year": "2021", "Month": "Oct", "Day": "24"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Icotinib, Almonertinib, and Olmutinib: A 2D Similarity/Docking-Based Study to Predict the Potential Binding Modes and Interactions into EGFR.", "Abstract": {"AbstractText": ["In the current study, a 2D similarity/docking-based study was used to predict the potential binding modes of icotinib, almonertinib, and olmutinib into EGFR. The similarity search of icotinib, almonertinib, and olmutinib against a database of 154 EGFR ligands revealed the highest similarity scores with erlotinib (0.9333), osimertinib (0.9487), and WZ4003 (0.8421), respectively. In addition, the results of the docking study of the three drugs into EGFR revealed high binding free energies (\u0394<i>G<sub>b</sub></i> = -6.32 to -8.42 kcal/mol) compared to the co-crystallized ligands (\u0394<i>G<sub>b</sub></i> = -7.03 to -8.07 kcal/mol). Analysis of the top-scoring poses of the three drugs was done to identify their potential binding modes. The distances between Cys797 in EGFR and the Michael acceptor sites in almonertinib and olmutinib were determined. In conclusion, the results could provide insights into the potential binding characteristics of the three drugs into EGFR which could help in the design of new more potent analogs."]}, "AuthorList": [{"Identifier": ["0000-0003-4048-1526"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Almalki", "ForeName": "Faisal A", "Initials": "FA"}, {"Identifier": ["0000-0002-3035-661X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Science and Technology Unit (STU), Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Central Laboratory for Micro-analysis, Minia University, Minia 61519, Egypt."}], "LastName": "Shawky", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0003-4770-9319"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Medicinal And Aromatic Plants Research Institute, National Center for Research, Khartoum 2404, Sudan."}], "LastName": "Abdalla", "ForeName": "Ashraf N", "Initials": "AN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal Chemistry Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt."}], "LastName": "Gouda", "ForeName": "Ahmed M", "Initials": "AM"}], "GrantList": [{"GrantID": "19-MED-1-01-0001", "Agency": "Deanship of Scientific Research at Umm Al-Qura University, Mekkah, KSA", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Acrylamides"}, {"RegistryNumber": "0", "NameOfSubstance": "Crown Ethers"}, {"RegistryNumber": "0", "NameOfSubstance": "Indoles"}, {"RegistryNumber": "0", "NameOfSubstance": "Ligands"}, {"RegistryNumber": "0", "NameOfSubstance": "Piperazines"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrimidines"}, {"RegistryNumber": "0", "NameOfSubstance": "Quinazolines"}, {"RegistryNumber": "9G6U5L461Q", "NameOfSubstance": "icotinib"}, {"RegistryNumber": "CHL9B67L95", "NameOfSubstance": "olmutinib"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}, {"RegistryNumber": "T4RS462G19", "NameOfSubstance": "aumolertinib"}], "MeshHeadingList": [{"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Acrylamides"}, {"QualifierName": ["drug effects"], "DescriptorName": "Binding Sites"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Crown Ethers"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Indoles"}, {"QualifierName": [], "DescriptorName": "Ligands"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Piperazines"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Pyrimidines"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Quinazolines"}], "CoiStatement": "Authors declared that there is no conflict of interest and have approved the article."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Singh D.B., Pathak R.K. In: Computational Approaches in Drug Designing and Their Applications BT\u2014Experimental Protocols in Biotechnology. Gupta N., Gupta V., editors. Springer US; New York, NY, USA: 2020. pp. 95\u2013117.", "ArticleIdList": ["10.1007/978-1-0716-0607-0_6"]}, {"Citation": "Ou-Yang S., Lu J., Kong X., Liang Z., Luo C., Jiang H. Computational drug discovery. Acta Pharmacol. Sin. 2012;33:1131\u20131140. doi: 10.1038/aps.2012.109.", "ArticleIdList": ["10.1038/aps.2012.109", "PMC4003107", "22922346"]}, {"Citation": "Faezov B., Dunbrack R.L.J. PDBrenum: A webserver and program providing Protein Data Bank files renumbered according to their UniProt sequences. PLoS ONE. 2021;16:e0253411. doi: 10.1371/journal.pone.0253411.", "ArticleIdList": ["10.1371/journal.pone.0253411", "PMC8259974", "34228733"]}, {"Citation": "Deschamps J.R. The role of crystallography in drug design. AAPS J. 2005;7:E813\u2013E819. doi: 10.1208/aapsj070478.", "ArticleIdList": ["10.1208/aapsj070478", "PMC2750950", "16594633"]}, {"Citation": "Kumar A., Zhang K.Y.J. Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery. Front. Chem. 2018;6:315. doi: 10.3389/fchem.2018.00315.", "ArticleIdList": ["10.3389/fchem.2018.00315", "PMC6068280", "30090808"]}, {"Citation": "Bajusz D., R\u00e1cz A., H\u00e9berger K. Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J. Cheminform. 2015;7:20. doi: 10.1186/s13321-015-0069-3.", "ArticleIdList": ["10.1186/s13321-015-0069-3", "PMC4456712", "26052348"]}, {"Citation": "Miranda-Quintana R.A., Bajusz D., R\u00e1cz A., H\u00e9berger K. Differential Consistency Analysis: Which Similarity Measures can be Applied in Drug Discovery? Mol. Inform. 2021;40:2060017. doi: 10.1002/minf.202060017.", "ArticleIdList": ["10.1002/minf.202060017", "33891369"]}, {"Citation": "Wang G., Zhu W. Molecular docking for drug discovery and development: A widely used approach but far from perfect. Future Med. Chem. 2016;8:1707\u20131710. doi: 10.4155/fmc-2016-0143.", "ArticleIdList": ["10.4155/fmc-2016-0143", "27578269"]}, {"Citation": "Meng X.-Y., Zhang H.-X., Mezei M., Cui M. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des. 2011;7:146\u2013157. doi: 10.2174/157340911795677602.", "ArticleIdList": ["10.2174/157340911795677602", "PMC3151162", "21534921"]}, {"Citation": "Xu X., Yan C., Zou X. Improving binding mode and binding affinity predictions of docking by ligand-based search of protein conformations: Evaluation in D3R grand challenge 2015. J. Comput. Aided Mol. Des. 2017;31:689\u2013699. doi: 10.1007/s10822-017-0038-1.", "ArticleIdList": ["10.1007/s10822-017-0038-1", "PMC5711532", "28668990"]}, {"Citation": "Poon C.C., Kelly J.J. Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer. Int. J. Cancer. 2017;140:1945\u20131954. doi: 10.1002/ijc.30533.", "ArticleIdList": ["10.1002/ijc.30533", "27874172"]}, {"Citation": "Mohamed F.A., Gomaa H.A., Hendawy O., Ali A.T., Farghaly H.S., Gouda A.M., Abdelazeem A.H., Abdelrahman M.H., Trembleau L., Youssif B.G. Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic antiproliferative activity. Bioorg. Chem. 2021;112:104960. doi: 10.1016/j.bioorg.2021.104960.", "ArticleIdList": ["10.1016/j.bioorg.2021.104960", "34020242"]}, {"Citation": "Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209\u2013249. doi: 10.3322/caac.21660.", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Ayati A., Moghimi S., Salarinejad S., Safavi M., Pouramiri B., Foroumadi A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg. Chem. 2020;99:103811. doi: 10.1016/j.bioorg.2020.103811.", "ArticleIdList": ["10.1016/j.bioorg.2020.103811", "32278207"]}, {"Citation": "Gagic Z., Ruzic D., Djokovic N., Djikic T., Nikolic K. In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs. Front. Chem. 2020;7:873. doi: 10.3389/fchem.2019.00873.", "ArticleIdList": ["10.3389/fchem.2019.00873", "PMC6960140", "31970149"]}, {"Citation": "Cohen P., Cross D., J\u00e4nne P.A. Kinase drug discovery 20 years after imatinib: Progress and future directions. Nat. Rev. Drug Discov. 2021;20:551\u2013569. doi: 10.1038/s41573-021-00195-4.", "ArticleIdList": ["10.1038/s41573-021-00195-4", "PMC8127496", "34002056"]}, {"Citation": "Tan F., Shen X., Wang D., Xie G., Zhang X., Ding L., Hu Y., He W., Wang Y., Wang Y. Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer. 2012;76:177\u2013182. doi: 10.1016/j.lungcan.2011.10.023.", "ArticleIdList": ["10.1016/j.lungcan.2011.10.023", "22112293"]}, {"Citation": "Yang J.C.-H., Camidge D.R., Yang C.-T., Zhou J., Guo R., Chiu C.-H., Chang G.-C., Shiah H.-S., Chen Y., Wang C.-C., et al. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J. Thorac. Oncol Off. Publ. Int. Assoc. Study Lung Cancer. 2020;15:1907\u20131918. doi: 10.1016/j.jtho.2020.09.001.", "ArticleIdList": ["10.1016/j.jtho.2020.09.001", "32916310"]}, {"Citation": "Zhou C., Xie L., Liu W., Zhang L., Zhou S., Wang L., Chen J., Li H., Zhao Y., Zhu B., et al. Absorption, metabolism, excretion, and safety of [(14)C]almonertinib in healthy Chinese subjects. Ann. Transl. Med. 2021;9:867. doi: 10.21037/atm-21-1606.", "ArticleIdList": ["10.21037/atm-21-1606", "PMC8184462", "34164501"]}, {"Citation": "Kim E.S. Olmutinib: First Global Approval. Drugs. 2016;76:1153\u20131157. doi: 10.1007/s40265-016-0606-z.", "ArticleIdList": ["10.1007/s40265-016-0606-z", "27357069"]}, {"Citation": "Hu X., Tang S., Yang F., Zheng P., Xu S., Pan Q., Zhu W. Design, Synthesis, and Antitumor Activity of Olmutinib Derivatives Containing Acrylamide Moiety. Molecules. 2021;26:3041. doi: 10.3390/molecules26103041.", "ArticleIdList": ["10.3390/molecules26103041", "PMC8160875", "34065165"]}, {"Citation": "Fu D.Y., Meiler J. Predictive Power of Different Types of Experimental Restraints in Small Molecule Docking: A Review. J. Chem. Inf. Model. 2018;58:225\u2013233. doi: 10.1021/acs.jcim.7b00418.", "ArticleIdList": ["10.1021/acs.jcim.7b00418", "29286651"]}, {"Citation": "Fu D.Y., Meiler J. RosettaLigandEnsemble: A Small-Molecule Ensemble-Driven Docking Approach. ACS Omega. 2018;3:3655\u20133664. doi: 10.1021/acsomega.7b02059.", "ArticleIdList": ["10.1021/acsomega.7b02059", "PMC5928483", "29732444"]}, {"Citation": "Yan X., Liao C., Liu Z., Hagler A.T., Gu Q., Xu J. Chemical Structure Similarity Search for Ligand-based Virtual Screening: Methods and Computational Resources. Curr. Drug Targets. 2016;17:1580\u20131585. doi: 10.2174/1389450116666151102095555.", "ArticleIdList": ["10.2174/1389450116666151102095555", "26521773"]}, {"Citation": "Dobi K., Hajd\u00fa I., Flachner B., Fab\u00f3 G., Szaszk\u00f3 M., Bogn\u00e1r M., Magyar C., Simon I., Szisz D., L\u0151rincz Z., et al. Combination of 2D/3D ligand-based similarity search in rapid virtual screening from multimillion compound repositories. Selection and biological evaluation of potential PDE4 and PDE5 inhibitors. Molecules. 2014;19:7008\u20137039. doi: 10.3390/molecules19067008.", "ArticleIdList": ["10.3390/molecules19067008", "PMC6270928", "24879613"]}, {"Citation": "Backman T.W.H., Cao Y., Girke T. ChemMine tools: An online service for analyzing and clustering small molecules. Nucleic Acids Res. 2011;39:W486\u2013W491. doi: 10.1093/nar/gkr320.", "ArticleIdList": ["10.1093/nar/gkr320", "PMC3125754", "21576229"]}, {"Citation": "Dassault Systems BIOVIA . Discovery Studio Visualizer, v16.1.0.15350. Dassault Systems; San Diego, CA, USA: 2016."}, {"Citation": "Molsoft L.L.C. Drug-Likeness and Molecular Property Prediction.  [(accessed on 29 June 2021)].  Available online:  http://molsoft.com/mprop/"}, {"Citation": "Luo Z., Gyawali B., Han S., Shi L., Guan X., Wagner A.K. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China. Semin Oncol. 2021;48:141\u2013144. doi: 10.1053/j.seminoncol.2021.03.001.", "ArticleIdList": ["10.1053/j.seminoncol.2021.03.001", "33875231"]}, {"Citation": "Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785\u20132791. doi: 10.1002/jcc.21256.", "ArticleIdList": ["10.1002/jcc.21256", "PMC2760638", "19399780"]}, {"Citation": "Laskowski R.A., Swindells M.B. LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 2011;51:2778\u20132786. doi: 10.1021/ci200227u.", "ArticleIdList": ["10.1021/ci200227u", "21919503"]}, {"Citation": "Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002;277:46265\u201346272. doi: 10.1074/jbc.M207135200.", "ArticleIdList": ["10.1074/jbc.M207135200", "12196540"]}, {"Citation": "Hirano T., Yasuda H., Tani T., Hamamoto J., Oashi A., Ishioka K., Arai D., Nukaga S., Miyawaki M., Kawada I., et al. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 2015;6:38789\u201338803. doi: 10.18632/oncotarget.5887.", "ArticleIdList": ["10.18632/oncotarget.5887", "PMC4770737", "26515464"]}, {"Citation": "Yosaatmadja Y., Silva S., Dickson J.M., Patterson A.V., Smaill J.B., Flanagan J.U., Mckeage M., Squire C.J. Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. J. Struct. Biol. 2015;192:539\u2013544. doi: 10.1016/j.jsb.2015.10.018.", "ArticleIdList": ["10.1016/j.jsb.2015.10.018", "26522274"]}, {"Citation": "Cross D.A.E., Ashton S.E., Ghiorghiu S., Eberlein C., Nebhan C.A., Spitzler P.J., Orme J.P., Finlay M.R.V., Ward R.A., Mellor M.J., et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046\u20131061. doi: 10.1158/2159-8290.CD-14-0337.", "ArticleIdList": ["10.1158/2159-8290.CD-14-0337", "PMC4315625", "24893891"]}, {"Citation": "Zhu S.-J., Zhao P., Yang J., Ma R., Yan X.-E., Yang S.-Y., Yang J.-W., Yun C.-H. Structural insights into drug development strategy targeting EGFR T790M/C797S. Oncotarget. 2018;9:13652\u201313665. doi: 10.18632/oncotarget.24113.", "ArticleIdList": ["10.18632/oncotarget.24113", "PMC5862605", "29568384"]}, {"Citation": "Shawky A.M., Ibrahim N.A., Abdalla A.N., Abourehab M.A.S., Gouda A.M. Novel pyrrolizines bearing 3,4,5-trimethoxyphenyl moiety: Design, synthesis, molecular docking, and biological evaluation as potential multi-target cytotoxic agents. J. Enzym. Inhib. Med. Chem. 2021;36:1313\u20131333. doi: 10.1080/14756366.2021.1937618.", "ArticleIdList": ["10.1080/14756366.2021.1937618", "PMC8221158", "34154478"]}, {"Citation": "Shawky A.M., Abdalla A.N., Ibrahim N.A., Abourehab M.A.S., Gouda A.M. Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors: Design, synthesis, cytotoxicity, and MDR reversal activities. Eur. J. Med. Chem. 2021;218:113403. doi: 10.1016/j.ejmech.2021.113403.", "ArticleIdList": ["10.1016/j.ejmech.2021.113403", "33823396"]}, {"Citation": "Almalki F.A., Abdalla A.N., Shawky A.M., El Hassab M.A., Gouda A.M. In Silico Approach Using Free Software to Optimize the Antiproliferative Activity and Predict the Potential Mechanism of Action of Pyrrolizine-Based Schiff Bases. Molecules. 2021;26:4002. doi: 10.3390/molecules26134002.", "ArticleIdList": ["10.3390/molecules26134002", "PMC8271847", "34209011"]}, {"Citation": "Shawky A.M., Ibrahim N.A., Abourehab M.A.S., Abdalla A.N., Gouda A.M. Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea/thiourea moieties with potential cytotoxicity and CDK inhibitory activities. J. Enzym. Inhib. Med. Chem. 2021;36:15\u201333. doi: 10.1080/14756366.2020.1837124.", "ArticleIdList": ["10.1080/14756366.2020.1837124", "PMC7594867", "33103497"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "9", "Day": "28"}, {"Year": "2021", "Month": "10", "Day": "20"}, {"Year": "2021", "Month": "10", "Day": "21"}, {"Year": "2021", "Month": "11", "Day": "13", "Hour": "1", "Minute": "12"}, {"Year": "2021", "Month": "11", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "24"}], "PublicationStatus": "epublish", "ArticleIdList": ["34770832", "PMC8588130", "10.3390/molecules26216423", "molecules26216423"]}}], "PubmedBookArticle": []}